Company intelligence / Profile preview

NNTT

Ownership: Private
Development stage: Other

Overview

NTT Biopharma develops a proprietary mesoporous silica nanoparticle platform to optimize drug delivery for difficult-to-treat conditions such as brain cancer and ocular diseases. The company has its own pipeline of nano-formulated products and offers contract research services in formulation development, process optimization, non-GMP supply, and preliminary efficacy studies. No published late-stage or commercial results are available yet

Therapeutic areas: OncologyOphthalmologyImmunology
Modalities: NanoparticleSmall molecule (nano-formulated)Nanomedicine
Industry: Biotech

Partnerships

Partners with pharmaceutical companies seeking improved drug delivery solutions via their MSN platform.Offers contract research services to external pharma partners.

Beyond the preview

Go deeper on NNTT.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NNTT.

Explore the full profile